Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss updates in HCC and GI cancers from the 2024 ESMO Congress.
EP. 1: 5-Year Follow-Up Data for Tremelimumab Plus Durvalumab in Unresectable HCC
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on 5-year data for tremelimumab plus durvalumab in unresectable HCC.
EP. 2: The STRIDE Regimen vs Atezolizumab/Bevacizumab: Selecting a Treatment Regimen in Unresectable HCC
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on tremelimumab/durvalumab vs atezolizumab/bevacizumab in unresectable HCC.
Experts Highlight Noteworthy Research From the 2024 ESMO Congress
MR-Linac Radiotherapy Limits Target Volume, Brain Tissue Exposure in High-Grade Glioma
PFS Data for 177Lu-Dotatate Surpass Clinical Benchmarks in Refractory Meningioma
Nivolumab Plus Radiotherapy Reduces Rates of Biochemical Recurrence in Gleason Grade 5 Prostate Cancer